Projects per year
Fingerprint Dive into the research topics where Christopher Vinnard is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 9 Similar Profiles
Meningeal Tuberculosis
Medicine & Life Sciences
Tuberculosis
Medicine & Life Sciences
HIV
Medicine & Life Sciences
Infection
Medicine & Life Sciences
Latent Tuberculosis
Medicine & Life Sciences
Therapeutics
Medicine & Life Sciences
Isoniazid
Medicine & Life Sciences
Rifampin
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects 2016 2019
- 1 Finished
Rifampicin Malabsorption In Hiv+ Patients: Mechanisms And Recovery After Haart
National Institutes of Health (NIH)
3/1/16 → 1/31/19
Project: Research project
Rifampin
HIV
Tuberculosis
Botswana
Research Personnel
Research Output 2008 2019
Adipose tissue regulates pulmonary pathology during TB infection
Ayyappan, J. P., Ganapathi, U., Lizardo, K., Vinnard, C., Subbian, S., Perlin, D. & Nagajyothi, J., Mar 1 2019, In : mBio. 10, 2, e02771-18.Research output: Contribution to journal › Article
Open Access
Mycobacterium tuberculosis
Adipose Tissue
Tuberculosis
Pathology
Lung
Attainment of target rifampicin concentrations in cerebrospinal fluid during treatment of tuberculous meningitis
Mezochow, A., Thakur, K. T., Zentner, I., Subbian, S., Kagan, L. & Vinnard, C., Jul 1 2019, In : International Journal of Infectious Diseases. 84, p. 15-21 7 p.Research output: Contribution to journal › Article
Open Access
Meningeal Tuberculosis
Rifampin
Cerebrospinal Fluid
Microbial Sensitivity Tests
Therapeutics
2
Citations
(Scopus)
Dual β-lactam combinations highly active against mycobacterium abscessus complex in vitro
Pandey, R., Chen, L., Manca, C., Jenkins, S., Glaser, L., Vinnard, C., Stone, G., Lee, J., Mathema, B., Nuermberger, E. L., Bonomo, R. A. & Kreiswirth, B., Jan 1 2019, In : mBio. 10, 1, e02895-18.Research output: Contribution to journal › Article
Open Access
Lactams
Ceftazidime
Mycobacterium
Imipenem
Anti-Bacterial Agents
Guidelines-based treatment associated with improved economic outcomes in non-tuberculous mycobacterial lung disease
Marras, T. K., Mirsaeidi, M., Vinnard, C., Chan, E. D., Eagle, G., Zhang, R., Wang, P. & Zhang, Q., Jan 1 2019, In : Journal of Medical Economics.Research output: Contribution to journal › Article
Open Access
Lung Diseases
Economics
Guidelines
Health Expenditures
Therapeutics
Assessing response to therapy for nontuberculous mycobacterial lung disease: Quo vadis?
Vinnard, C., Mezochow, A., Oakland, H., Klingsberg, R., Hansen-Flaschen, J. & Hamilton, K., Nov 20 2018, In : Frontiers in Microbiology. 9, NOV, 02813.Research output: Contribution to journal › Review article
Lung Diseases
Biomarkers
Therapeutics
Pharmaceutical Preparations
Standard of Care